Stock HUMDF HUA MEDICINE (SHANGHAI) LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Hua Medicine (Shanghai) Ltd. OTC Markets

Equities

HUMDF

KYG4644K1022

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 13:33:26 2023-06-07 EDT 		5-day change 1st Jan Change
0.2028 USD -54.93% Intraday chart for Hua Medicine (Shanghai) Ltd. -.--% -.--%
03-28 Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 CI

Business Summary

Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.

Number of employees: 177

Sales per Business

HKD in Million2022Weight2023Weight Delta
Dorzagliatin
100.0 %
20 100.0 % 85 100.0 % +313.64%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
100.0 %
20 100.0 % 85 100.0 % +313.64%

Managers

Managers TitleAgeSince
Li Chen FOU
 Founder 61 09-11-09
Li Changhong CTO
 Chief Tech/Sci/R&D Officer 55 -
Di Hong COO
 Chief Operating Officer 45 21-04-30
Yun Long Du CTO
 Chief Tech/Sci/R&D Officer - 17-08-11
Fuxing Tang CTO
 Chief Tech/Sci/R&D Officer 57 20-02-12
Yi Zhang CTO
 Chief Tech/Sci/R&D Officer - 18-03-31
Chien Cheng Lin BRD
 Director/Board Member 53 18-09-12
Wenjie Xu SAM
 Sales & Marketing 52 18-08-08
Wing Yan Yuen SEC
 Corporate Secretary 53 19-12-30

Members of the board

Members of the board TitleAgeSince
Robert Nelsen CHM
 Chairman 60 10-04-22
William Keller BRD
 Director/Board Member 75 -
Yiu Wa Tsui BRD
 Director/Board Member 74 18-08-31
Li Chen FOU
 Founder 61 09-11-09
Yi Zhang CTO
 Chief Tech/Sci/R&D Officer - 18-03-31
Chien Cheng Lin BRD
 Director/Board Member 53 18-09-12
Yiu Leung Cheung BRD
 Director/Board Member 64 22-12-31
Fang Xin Li BRD
 Director/Board Member 32 23-10-11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,055,588,761 911,594,906 ( 86.36 %) 75,066,704 ( 7.111 %) 86.36 %

Shareholders

NameEquities%Valuation
Fang Hong Xing
3.337 %
35,220,690 3.337 % 7 M $
Chien Cheng Lin
0.8052 %
8,499,295 0.8052 % 2 M $
CRUX Asset Management Ltd.
0.3851 %
4,065,069 0.3851 % 826 388 $
Li Chen
0.3427 %
3,618,000 0.3427 % 735 503 $
ICBC Credit Suisse Asset Management Co., Ltd.
0.0531 %
560,000 0.0531 % 113 842 $
Fullgoal Fund Management Co., Ltd.
0.0171 %
180,000 0.0171 % 36 592 $
The Core Trust Co., Ltd.
0.000000 %
0 0.000000 % - $

Company contact information

Hua Medicine Ltd.

Lane 36, Xuelin Road Building 2

201203, Shanghai

+

http://www.huamedicine.com
address Hua Medicine (Shanghai) Ltd.(HUMDF)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.49
Average target price
-
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+19.14% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.46% 108B
BIONTECH SE Stock BioNTech SE
-4.43% 24.57B
ARGENX SE Stock argenx SE
+3.23% 22.82B
GENMAB A/S Stock Genmab A/S
-10.44% 18.19B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.54B
BEIGENE, LTD. Stock BeiGene, Ltd.
-12.37% 16.5B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.82% 13.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.91% 11.1B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2552 Stock
  4. HUMDF Stock
  5. Company Hua Medicine (Shanghai) Ltd.